Search Results for "Latest News On Tirofiban"
Original Source: Safety evaluation of tirofiban.
Importance of the field: Heightened platelet activity is pivotal in the thrombosis underlying acute coronary syndrome (ACS). The glycoprotein IIb/IIIa inhibitor tirofiban is a powerful platelet inhibitor with demonstrated efficacy and safety across the spectrum of ACS. Despite tirofiban's impact on the platelet compared with placebo, only an excess in minor and importantly not major bleeding has been observed. Thrombocytopenia with tirofiban seems to be extremely rare and immediately reversible on infusion...
Matching Channels
For the latest news on mergers and acquisitions in the industry, try the BioPortfolio Twitter feed and Facebook pages . . . (coming soon!)
Biotherapeutics - news, views, reports and blogs
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Latest Biotherapeutics News - RSS feed - Twitter account - @Biotherapeutic1 -...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Latest Pharmaceutical and Biotechnology Collabor...
Biosimilars - news, reports, views and blogs
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusi...
Diagnostics - news, views, blogs
A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease...
Matching News
Tirofiban Risky After Thrombectomy in Acute Ischemic Stroke
Patients who received tirofiban with mechanical thrombectomy for acute ischemic stroke had a higher risk of fatal intracerebral hemorrhage (ICH) and poor outcome in a recent observational study. Reu...
Aggrastat tirofiban regulatory update
Aggrastat tirofiban: Phase II started
Medicure develops Aggrastat transdermal delivery formulation
Medicure has developed a transdermal delivery formulation for its AGGRASTAT (tirofiban Hcl) drug for treating acute coronary syndromes.
Tirofiban effectively prevents strokes in high risk patients
Scientists may have discovered a new way to prevent strokes in high risk patients, according to research from the University of Warwick and University Hospitals Coventry and Warwickshire (UHCW).
WINNIPEG, MANITOBA -- (Marketwire) -- 09/26/12 -- Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE: MPH)(PINKSHEETS: MCUJ), is pleased to announce the development of a transdermal delivery ...
Medicure signs deal to promote Aggrastat in Puerto Rico
Medicure Pharma, a wholly-owned subsidiary of Medicure, has signed deal for the promotion of Aggrastat (tirofiban HCl) in Puerto Rico.
Latest News From "The Pink Sheet" DAILY - News From ADA
J&J's Canagliflozin Positive Phase III Data In The Limelight At ADA
Matching PubMed Articles
To prevent thrombosis in high-risk acute coronary syndrome patients undergoing percutaneous coronary intervention for re-vascularisation, concomitant administration of a glycoprotein IIb/IIIa inhibito...
The latest news in fuel cells and batteries.
Safety evaluation of tirofiban.
Importance of the field: Heightened platelet activity is pivotal in the thrombosis underlying acute coronary syndrome (ACS). The glycoprotein IIb/IIIa inhibitor tirofiban is a powerful platelet inhibi...
PURPOSE: Glycoprotein IIb/IIIa inhibitors are favourable in ST-elevation myocardial infarction (STEMI) patients, and the additional value of early pre-hospital high bolus dose tirofiban has recently b...
OBJECTIVES: To investigate whether tirofiban would have been non-inferior to abciximab had the trial completed enrollment and place the termination of this trial in a broader research ethics context....
